Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2024-09-25 DOI:10.1016/j.vaccine.2024.126385

Célya Danzelle , Patricia Cunha , Pablo Gomes Noleto , Florence B. Gilbert , Kamila Reis Santos , Christophe Staub , Anne Pinard , Alain Deslis , Sarah Barbey , Pierre Germon , Johan-Owen De Craene , Pascal Rainard , Marc Blondel , Rodrigo Prado Martins

{"title":"Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis","authors":"Célya Danzelle , Patricia Cunha , Pablo Gomes Noleto , Florence B. Gilbert , Kamila Reis Santos , Christophe Staub , Anne Pinard , Alain Deslis , Sarah Barbey , Pierre Germon , Johan-Owen De Craene , Pascal Rainard , Marc Blondel , Rodrigo Prado Martins","doi":"10.1016/j.vaccine.2024.126385","DOIUrl":null,"url":null,"abstract":"<div><div>Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine <em>in vitro, ex vivo,</em> and <em>in vivo</em> approaches to evaluate the potential of the yeast <em>Saccharomyces cerevisiae</em> as a platform for novel vaccines against bovine mastitis. We demonstrate that <em>S. cerevisiae</em> is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of <em>S. cerevisiae</em> antigens are necessary for the development of successful vaccine candidates.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24010673","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine in vitro, ex vivo, and in vivo approaches to evaluate the potential of the yeast Saccharomyces cerevisiae as a platform for novel vaccines against bovine mastitis. We demonstrate that S. cerevisiae is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of S. cerevisiae antigens are necessary for the development of successful vaccine candidates.

查看原文本刊更多论文

将酿酒酵母菌作为牛乳腺炎疫苗接种平台

乳腺炎是乳制品行业的一个主要问题。尽管进行了多次尝试，但现有乳腺炎疫苗的功效有限，原因在于它们无法引发强大的细胞介导免疫。最近，人们发现酵母是一种很有前景的抗原载体，能够诱导 T 细胞应答，超越了传统佐剂疫苗诱导的抗体偏倚机制。在本研究中，我们将体外、体内和体外方法结合起来，评估了酿酒酵母作为新型牛乳腺炎疫苗平台的潜力。我们证明酵母菌可安全用于奶牛的肌肉注射和乳房内免疫。接种疫苗后，针对酵母平台的 IFNγ 和 IL-17 反应显著增加，但针对疫苗抗原的反应却没有增加。这些观察结果表明，要开发出成功的候选疫苗，就必须采取策略来平衡麦角酵母菌抗原的免疫优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.